Current Research Studies
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy
Marinus 1042-TSC-3002
What is the goal of the study?
This is a Phase 3, multi-site open label study of adjunctive Ganaxolone (GNX) treatment in children and adults with Tuberous Sclerosis Complex (TSC)-related epilepsy. It is anticipated about 169 participants from Study 1042-TSC-3001 and Study 1042-TSC-2001 will be enrolled in this OLE study and continue treatment with GNX. TSC is one of the most common genetic causes of epilepsy. Seizure types and presentations vary by age. The primary objective is to evaluate the long-term safety and tolerability of GNX as adjunctive therapy for seizures associated with TSC in children and adults.
Who can participate in the study?
Please contact the study team listed below to learn more.